Article
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
The oncologist - 1 Jan 2011
Kamal Arif H, Loprinzi Charles L, Reynolds Carol, Dueck Amylou C, Geiger Xochiquetzal J, Ingle James N, Carlson Robert W, Hobday Timothy J, Winer Eric P, Goetz Matthew P
Abstract excerpt
BACKGROUND: Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX®; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria. METHODS: Standard demographic and tumor prognostic criteria...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.